Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer

BACKGROUND: Napabucasin is an oral NAD(P)H:quinone oxidoreductase 1 bioactivatable agent that generates reactive oxygen species, is hypothesised to affect multiple oncogenic cellular pathways, including STAT-3, and is expected to result in cancer cell death. This phase I study investigated the safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hiroya, Masuishi, Toshiki, Kawazoe, Akihito, Muro, Kei, Kadowaki, Shigenori, Bando, Hideaki, Iino, Shuichi, Kageyama, Rie, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520863/
https://www.ncbi.nlm.nih.gov/pubmed/34291369
http://dx.doi.org/10.1007/s10147-021-01987-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520863/
https://www.ncbi.nlm.nih.gov/pubmed/34291369
http://dx.doi.org/10.1007/s10147-021-01987-9

Ejemplares similares